Drug Pipeline Update

Drug Insights ➤ August 2016

New drug information

- **Adlyxin™ (lixisenatide):** The Food and Drug Administration (FDA) approved Sanofi and Zealand’s Adlyxin to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. Adlyxin is a once-daily mealtime glucagon-like peptide-1 receptor agonist (GLP-1 RA). Adlyxin will compete with Victoza®, Byetta®, Bydureon®, Tanzeum™ and Trulicity®.

- **Qbrelis™ (lisinopril oral solution 1 mg/mL):** The FDA approved Silvergate Pharmaceuticals’ Qbrelis for the treatment of hypertension (high blood pressure) in adult patients and pediatric patients 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction in adults. Qbrelis is the first and only FDA-approved lisinopril oral solution.

- **Sustol® (granisetron extended-release injection):** The FDA approved Heron Therapeutics’ Sustol for prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). Sustol should be administered subcutaneously by a health care provider.

- **Troyca® ER (oxycodone/naltrexone extended release):** The FDA approved Pfizer’s Troyca ER for the management of pain that requires around-the-clock long-term opioid treatment and for which alternative treatment options are inadequate. Troyca ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal routes.

New generics

- **Zegerid® (omeprazole/sodium bicarbonate powder packet for susp, 20-1680 mg, 40-1680 mg):** Oceanside has launched the first generic version of Valeant’s Zegerid powder packets for the treatment of duodenal ulcer, GERD, and to maintain healing of erosive esophagitis. The 40 mg/1680 mg dose is indicated for the reduction of risk of upper GI bleeding in critically ill patients.

While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. All brand names are property of their respective owners.